HIV/HCV Drug Litigation

Commonly-prescribed drugs manufactured by Gilead Sciences, Inc. for the treatment and prevention of HIV and HCV have been shown to produce toxic side effects such as kidney disease, kidney failure, bone mineral density loss, bones fractures, bone breaks, and other debilitating bone and kidney conditions.

These drugs include all TDF-based medication and combination pill Gilead manufactures:

  • Viread (tenofovir disoproxil fumarate, TDF)
  • Truvada (TDF and emtricitabine) (including when taken for PrEP)
  • Atripla (TDF, efavirenz, and emtricitabine)
  • Complera (TDF, emtricitabine, and rilpivirine)
  • Stribild (TDF, elvitegravir, cobicistat, and emtricitabine)


If you or a loved one developed serious bone or kidney issues after taking any of these TDF-based drugs, you may be entitled to significant financial compensation.

As uncovered by our partners in this litigation before they filed the first state and federal lawsuits for personal injuries caused by Gilead’s TDF drugs, Gilead representatives were aware that the drugs could cause permanent bone and kidney damage, and deliberately chose not to warn patients and physicians of these dangers. The lawsuits also allege that Gilead intentionally stalled the release of a safer version of these popular and commonly-prescribed HIV medications—now known as TAF (Genvoya, Odefsey, Descovy) for over a decade so the company could reap monopolistic and outsized profits at the expense of public health.

Litigation remains one of the most effective ways to hold Gilead responsible and we plan to continue to build on the success and expertise developed from the first-filed lawsuits.

Please keep in mind that legal actions are time-sensitive and subject to strict statutes of limitation. To explore your legal options, we invite you to schedule a complimentary, no-obligation case review with our team of experienced pharmaceutical litigators. Please call 877-274-4497 or complete the form on this page to speak to an attorney.